Efficacy of oral lipid‐based formulations of apomorphine and its diester in a Parkinson's disease rat model

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Journal of pharmacy and pharmacology

• Publication date

  2017-06-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/jphp.12758PMID 28620913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Apomorphine and its esters: Differences in Caco-2 cell permeability and chylomicron affinity.

  2016cited by this paper
• In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs.

  2016cited by this paper
• Lipophilic prodrugs of apomorphine I: preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media.

  2015cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application

  2010cited by this paper
• Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes.

  2010cited by this paper
• Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds.

  2007cited by this paper
• Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.

  2005cited by this paper
• Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.

  2004cited by this paper
• Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.

  2002cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson’s Disease

  1999cited by this paper
• Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation.

  1998cited by this paper
• Stepwise Intravenous Infusion of Apomorphine to Determine the Therapeutic Window in Patients with Parkinson's Disease

  1998cited by this paper
• A study of tolerance to apomorphine

  1996cited by this paper
• L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study.

  1995cited by this paper
• Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms

  1989cited by this paper
• Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis.

  1980cited by this paper
• Photoelectrode with a very short time-constant for recording intracerebrally Ca2+ transients at a cellular level.

  1979cited by this paper
• Pulmonary Disease and Drug Kinetics

  1978cited by this paper
• Prolonged apomorphine-like behavioural effects of apomorphine esters.

  1976cited by this paper
• Diester derivatives as apomorphine prodrugs.

  1976cited by this paper
• Prolonged apomorphine-like behavioural effects of apomorphine esters

  1976cited by this paper
• DIESTER DERIVATIVES AS APOMORPHINE PRODRUGS

  1976influential reference
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper
• The effect of orphenadrine hydrochloride on the acetylcholine concentration in rat brain.

  1969cited by this paper

• Drug discovery and development for Parkinson’s disease: are preclinical models good enough?

  2025cites this paper
• Self-Emulsifying Drug Delivery Systems: An Alternative Approach to Improve Brain Bioavailability of Poorly Water-Soluble Drugs through Intranasal Administration

  2022influential citation
• Deciphering Spinal Endogenous Dopaminergic Mechanisms That Modulate Micturition Reflexes in Rats with Spinal Cord Injury

  2021cites this paper
• Controlled delivery of apomorphine through buccal mucosa, towards a noninvasive administration method in Parkinson's disease: a preclinical mechanistic study.

  2020cites this paper
• An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease

  2020cites this paper
• Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations

  2019cites this paper
• Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug.

  2018cites this paper
• Comprehensive Assessment of Curcumin as a Functional Food

  2018cites this paper
• Lipidic prodrug approach for improved oral drug delivery and therapy

  2018cites this paper
• ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability

  2018cites this paper
• Advances in prodrug design for Parkinson’s disease

  2018cites this paper
• Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease

  2017cites this paper